Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

BACKGROUND: In the current study we used contrast-enhanced T1 subtraction maps to test whether early changes in enhancing tumor volume are prognostic for overall survival (OS) in newly diagnosed glioblastoma (GBM) patients treated with chemoradiation with or without bevacizumab (BV). METHODS: Seven...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Ellingson, Benjamin M, Abrey, Lauren E, Garcia, Josep, Chinot, Olivier, Wick, Wolfgang, Saran, Frank, Nishikawa, Ryo, Henriksson, Roger, Mason, Warren P, Harris, Robert J, Leu, Kevin, Woodworth, Davis C, Mehta, Arnav, Raymond, Catalina, Chakhoyan, Ararat, Pope, Whitney B, Cloughesy, Timothy F
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6178278/
https://ncbi.nlm.nih.gov/pubmed/29897562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy064
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires